Roberto Buzzoni

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

Journal: ESMO open

Published: June 04, 2025

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.

Journal: Cancers

Published: November 11, 2021

Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies.

Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies.

Journal: Pancreas

Published: February 09, 2021

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.

Journal: Cancer

Published: October 15, 2020

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 30, 2019

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Journal: Tumori

Published: May 02, 2018

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

Journal: Endocrine-related cancer

Published: March 15, 2018

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

Journal: OncoTargets and therapy

Published: October 31, 2017

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Journal: Cancer science

Published: July 05, 2017

Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.

Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.

Journal: Future oncology (London, England)

Published: June 06, 2017

The underestimated role of somatostatin analogs in the NETTER-1 trial.

The underestimated role of somatostatin analogs in the NETTER-1 trial.

Journal: Future oncology (London, England)

Published: May 12, 2017

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 13, 2017

Showing 1-12 of 44

Last Updated: 09/26/2026